Is accuracy of serum free light chain measurement achievable?

Clinical Chemistry and Laboratory Medicine

Volumn 54, Issue 6, 2016, Pages 1021-1030

  Jacobs, Joannes F M ^a   Tate, Jillian R ^b   Merlini, Giampaolo ^c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^c UNIVERSITY OF PAVIA   (Italy)

Author keywords

free light chains; harmonisation; M protein; monoclonal gammopathy; plasma cell dyscrasia; standardisation

Indexed keywords

IMMUNOGLOBULIN LIGHT CHAIN; M PROTEIN; PLASMA PROTEIN;

ACUTE KIDNEY FAILURE; ANTIGEN RECOGNITION; ANTIGENICITY; ARTICLE; CAPILLARY ELECTROPHORESIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FREE LIGHT CHAIN ASSAY; GAMMOPATHY; HUMAN; IMMUNOASSAY; IMMUNOGLOBULIN BLOOD LEVEL; ISOELECTRIC POINT; KIDNEY FAILURE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; TURBIDIMETRY; BLOOD; IMMUNOLOGY; MEASUREMENT ACCURACY; PROCEDURES; PROTEIN ELECTROPHORESIS;

BLOOD PROTEIN ELECTROPHORESIS; DATA ACCURACY; HUMANS; IMMUNOASSAY; IMMUNOGLOBULIN LIGHT CHAINS; MULTIPLE MYELOMA;

EID: 84969799156     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2015-0879     Document Type: Article

References (63)

1. Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, et al. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood 2011;117:4701-5.
2. Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 2010;24:1121-7.
3. Bradwell AR, Carr-Smith HD, Mead GP, Tang LX, Showell PJ, Drayson MT, et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001;47:673-80.
4. Dispenzieri A, Katzmann JA, Kyle RA, Larson DR, Therneau TM, Colby CL, et al. Use of nonclonal serum immunoglobulin free light chains to predict overall survival in the general population. Mayo Clin Proc 2012;87:517-23.
5. Graziani MS, Merlini G. Serum free light chain analysis in the diagnosis and management of multiple myeloma and related conditions. ExpertRev Mol Diagn 2014;14:55-66.
6. Tate J, Bazeley S, Sykes S, Mollee P. Quantitative serum free light chain assay-analytical issues. Clin Biochem Rev 2009;30:131-40.
7. Campbell JP, Cobbold M, Wang Y, Goodall M, Bonney SL, Chamba A, et al. Development of a highly-sensitive multiplex assay using monoclonal antibodies for the simultaneous measurement of kappa and lambda immunoglobulin free light chains in serum and urine. J Immunol Methods 2013;391:1-13.
8. Davern S, Tang LX, Williams TK, Macy SD, Wall JS, Weiss DT, et al. Immunodiagnostic capabilities of anti-free immunoglobulin light chain monoclonal antibodies. Am J Clin Pathol 2008;130:702-11.
9. de Kat Angelino CM, Raymakers R, Teunesen MA, Jacobs JF, Klasen IS. Overestimation of serum kappa free light chain concentration by immunonephelometry. Clin Chem 2010;56:1188-90.
10. Nakano T, Nagata A. ELISAs for free human immunoglobulin light chains in serum: improvement of assay specificity by using two specific antibodies in a sandwich detection method. J Immunol Methods 2004;293:183-9.
11. te Velthuis H, Knop I, Stam P, van den Broek M, Bos HK, Hol S, et al. N Latex FLC-new monoclonal high-performance assays for the determination of free light chain kappa and lambda. Clin Chem Lab Med 2011;49:1323-32.
12. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009;23:215-24.
13. Abraham RS, Charlesworth MC, Owen BA, Benson LM, Katzmann JA, Reeder CB, et al. Trimolecular complexes of lambda light chain dimers in serum of a patient with multiple myeloma. Clin Chem 2002;48:1805-11.
14. Bosmann M, Kossler J, Stolz H, Walter U, Knop S, Steigerwald U. Detection of serum free light chains: the problem with antigen excess. Clin Chem Lab Med 2010;48:1419-22.
15. Jacobs JF, Hoedemakers RM, Teunissen E, Te Velthuis H. N Latex FLC serum free light-chain assays in patients with renal impairment. Clin Chem Lab Med 2014;52:853-9.
16. Jacobs JF, Hoedemakers RM, Teunissen E, van der Molen RG, Te Velthuis H. Effect of sample dilution on two free light chain nephelometric assays. Clin Chim Acta 2012;413;1708-9.
17. Tate J, Mollee P, Johnson R. Monoclonal gammopathies-clinical and laboratory issues. Clin Biochem Rev 2009;30:89-91.
18. Tate JR, Mollee P, Dimeski G, Carter AC, Gill D. Analytical performance of serum free light-chain assay during monitoring of patients with monoclonal light-chain diseases. Clin Chim Acta 2007;376:30-6.
19. Vercammen M, Meirlaen P, Broodtaerts L, Vande BI, Bossuyt X. Effect of sample dilution on serum free light chain concentration by immunonephelometric assay. Clin Chim Acta 2011;412: 1798-804.
20. Murata K, Clark RJ, Lockington KS, Tostrud LJ, Greipp PR, Katzmann JA. Sharply increased serum free light-chain concentrations after treatment for multiple myeloma. Clin Chem 2010;56:16-8.
21. Murng SH, Follows L, Whitfield P, Snowden JA, Swallow K, Green K, et al. Defining the impact of individual sample variability on routine immunoassay of serum free light chains (sFLC) in multiple myeloma. Clin Exp Immunol 2013;171:201-9.
22. Pattenden RJ, Rogers SY, Wenham PR. Serum free light chains; the need to establish local reference intervals. Ann Clin Biochem 2007;44:512-5.
23. Hoedemakers RM, Pruijt JF, Hol S, Teunissen E, Martens H, Stam P, et al. Clinical comparison of new monoclonal antibody-based nephelometric assays for free light chain kappa and lambda to polyclonal antibody-based assays and immunofixation electrophoresis. Clin Chem Lab Med 2011;50:489-95.
24. Lock RJ, Saleem R, Roberts EG, Wallage MJ, Pesce TJ, Rowbottom A, et al. A multicentre study comparing two methods for serum free light chain analysis. Ann Clin Biochem 2013;50:255-61.
25. Mollee P, Tate J, Pretorius CJ. Evaluation of the N Latex free light chain assay in the diagnosis and monitoring of AL amyloidosis. Clin Chem Lab Med 2013;51:2303-10.
26. Pretorius CJ, Klingberg S, Tate J, Wilgen U, Ungerer JP. Evaluation of the N Latex FLC free light chain assay on the Siemens BN analyser: precision, agreement, linearity and variation between reagent lots. Ann Clin Biochem 2012;49:450-5.
27. Schneider N, Wynckel A, Kolb B, Sablon E, Gillery P, Maquart FX. [Comparative analysis of immunoglobulin free light chains quantification by Freelite (The Binding Site) and N Latex FLC (Siemens) methods]. Ann Biol Clin (Paris) 2013;71:13-9.
28. Kim HS, Kim HS, Shin KS, Song W, Kim HJ, Kim HS, et al. Clinical comparisons of two free light chain assays to immunofixation electrophoresis for detecting monoclonal gammopathy. BioMed Res Int 2014;2014:647238.
29. International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003;121:749-57.
30. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3-9.
31. Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008;111:785-9.
32. Kastritis E, Terpos E, Moulopoulos L, Spyropoulou-Vlachou M, Kanellias N, Eleftherakis-Papaiakovou E, et al. Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease. Leukemia 2013;27:947-53.
33. Larsen JT, Kumar SK, Dispenzieri A, Kyle RA, Katzmann JA, Rajkumar SV. Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma. Leukemia 2013;27: 941-6.
34. Waxman AJ, Mick R, Garfall AL, Cohen A, Vogl DT, Stadtmauer EA, et al. Classifying ultra-high risk smoldering myeloma. Leukemia 2015;29:751-3.
35. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014;15:e538-48.
36. Wang L, Chan PC. Measurement uncertainty for serum free light chain assays: estimation and implication on result interpretation. Clinical Biochem 2013;46:381-4.
37. Hutchison CA, Batuman V, Behrens J, Bridoux F, Sirac C, Dispenzieri A, et al. The pathogenesis and diagnosis of acute kidney injury in multiple myeloma. Nat Rev Nephrol 2012;8: 43-51.
38. Hutchison CA, Cockwell P, Cook M. Diagnostic accuracy of monoclonal antibody based serum immunoglobulin free light chain immunoassays in myeloma cast nephropathy. BMC Clin Pathol 2012;12:12.
39. Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia 2006;20:1467-73.
40. Snozek CL, Katzmann JA, Kyle RA, Dispenzieri A, Larson DR, Therneau TM, et al. Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system. Leukemia 2008;22:1933-7.
41. Kyrtsonis MC, Vassilakopoulos TP, Kafasi N, Sachanas S, Tzenou T, Papadogiannis A, et al. Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma. Br J Haematol 2007;137:240-3.
42. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007;110:827-32.
43. Munshi NC, Anderson KC, Bergsagel PL, Shaughnessy J, Palumbo A, Durie B, et al. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood 2011;117: 4696-700.
44. Jovanovich S, Tate J, Wheatland L, Mollee P, Jacobs JF. Report of 2013 RCPA serum free light chains (SFLC) quality assurance program (QAP) - A need for harmonisation [Abstract]. Clin Biochem Rev 2014;35:S46.
45. Van Duijn MM, Jacobs JF, Wevers RA, Engelke UF, Joosten I, Luider TM. Quantitative measurement of immunoglobulins and free light chains using mass spectrometry. Anal Chem 2015;87:8268-74.
46. Mills JR, Barnidge DR, Murray DL. Detecting monoclonal immunoglobulins in human serum using mass spectrometry. Methods 2015;81:56-65.
47. International Vocabulary of Metrology-Basic and General Concepts and Associated Terms (VIM 3rd ed.). JCGM, 2012(200).
48. Panteghini M. Traceability, reference systems and result comparability. Clin Biochem Rev 2007;28:97-104.
49. Schimmel H, Zegers I. Performance criteria for reference measurement procedures and reference materials. Clin Chem Lab Med 2015;53:899-904.
50. Campbell JP, Stride AE, Brioli A, Coodall M, Morgen CJ, Drayson MT. Seralite rapid point-of-care detection of free light chain escape, non-secretory relapse and light chain only relapse in multiple myeloma [Abstract]. Blood 2013;122:3136.
51. Nakano T, Miyazaki S, Takahashi H, Matsumori A, Maruyama T, Komoda T, et al. Immunochemical quantification of free immunoglobulin light chains from an analytical perspective. Clin Chem Lab Med 2006;44:522-32.
52. Solomon A, Weiss DT. Structural and functional properties of human lambda-light-chain variable-region subgroups. Clin Diagn Lab Immunol 1995;2:387-94.
53. Lavatelli F, Brambilla F, Valentini V, Rognoni P, Casarini S, Di Silvestre D, et al. A novel approach for the purification and proteomic analysis of pathogenic immunoglobulin free light chains from serum. Biochim Biophys Acta 2011;1814:409-19.
54. Graziani M, Merlini G, Petrini C, Proteins ICoP, Proteins SISGo. Guidelines for the analysis of Bence Jones protein. Clin Chem Lab Med 2003;41:338-46.
55. Mead GP, Carr-Smith HD, Drew R, Drayson MT, Bradwell AR. Nephelometric measurement of serum free light chains in nonsecretory myeloma [Abstract]. Clin Chem 2002;48:A23.
56. Harding S, Provot F, Beuscart JB, Cook M, Bradwell AR, Stringer S, et al. Aggregated serum free light chains may prevent adequate removal by high cut-off haemodialysis. Nephrol Dial Transplant 2011;26:1438.
57. Kaplan B, Golderman S, Aizenbud B, Esev K, Kukuy O, Leiba M, et al. Immunoglobulin-free light chain monomer-dimer patterns help to distinguish malignant from premalignant monoclonal gammopathies: A pilot study. Am J Hematol 2014;89:882-8.
58. Di Noto G, Cimpoies E, Dossi A, Paolini L, Radeghieri A, Caimi L, et al. Polyclonal versus monoclonal immunoglobulin-free light chains quantification. Ann Clin Biochem 2015;52:327-36.
59. Palladini G, Russo P, Bosoni T, Verga L, Sarais G, Lavatelli F, et al. Identification of amyloidogenic light chains requires the combination of serum-free light chain assay with immunofixation of serum and urine. Clin Chem 2009;55:499-504.
60. Jacobs JF, de Kat Angelino CM, Raymakers R, Klasen IS. To the editor: Author reply. Clin Chem 2010;56:1504.
61. Mead GP, Carr-Smith HD. Overestimation of serum kappa free light chain concentration by immunonephelometry. Clin Chem 2010;56:1503-4.
62. Murray DL, Ryu E, Snyder MR, Katzmann JA. Quantitation of serum monoclonal proteins: relationship between agarose gel electrophoresis and immunonephelometry. Clin Chem 2009;55:1523-9.
63. Tillyer CR. The estimation of free light chains of immunoglobulins in biological fluids. Int J Clin Lab Res 1992;22:152-8.